|
|
Trading Halt: Halted at 4:02:06 p.m. ET - Trading Halt: Halt News Pending
|
|
|
|
Aardvark Therapeutics Creates Ardia Therapeutics Subsidiary; Appoints COO Bryan Jones As CEO
|
|
|
|
BTIG Reiterates Buy on Aardvark Therapeutics, Maintains $26 Price Target
|
|
|
|
Institutional Review Board Approves Amended Protocol To Aardvark Therapeutics' Ongoing Phase 3 HERO Trial Of ARD-101 for Hyperphagia In Individuals With Prader-Willi Syndrome, The amended protocol, submitted to FDA Lowers Minimum Age Of For Participation From 10 to 7 Years Old
|
|
|
|
HC Wainwright & Co. Reiterates Buy on Aardvark Therapeutics, Maintains $40 Price Target
|
|